The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Loss from operations | -13,552,334 |
| Sale of royalty and milestone rights, net | 0 |
| Interest expense | 822,709 |
| Interest income | 679,740 |
| Other income (expense), net | 296,029 |
| Net loss | -13,399,274 |
| Depreciation and amortization | 1,634,486 |
| Right-of-use asset - operating lease | -516,895 |
| Stock-based compensation expense | 1,496,562 |
| Loss on disposal of property and equipment | 0 |
| Non-cash royalty revenue related to sale of future royalties | -6,298 |
| Non-cash interest expense | 82,502 |
| Accounts receivable | 12,053 |
| Other receivables | 331,026 |
| Prepaid expenses | -668,486 |
| Deposits | 0 |
| Other current assets | 65,405 |
| Other non-current assets | 78,723 |
| Operating lease liability | -548,638 |
| Accounts payable | -255,146 |
| Accrued expenses | -2,250,627 |
| Interest payable | 572,561 |
| Deferred grant funding | -3,089,828 |
| Deferred revenue | -1,000,000 |
| Net cash (used in) provided by operating activities | -9,885,870 |
| Purchases of property and equipment | 385,278 |
| Net cash used in investing activities | -385,278 |
| Net proceeds from issuance of common stock | 20,930,126 |
| Payments of deferred offering costs | 321,686 |
| Repayment of liability on sale of future royalties | 0 |
| Issuance of note payable | 486,721 |
| Payments on note payable | 553,829 |
| Principal payments on finance lease | 1,264,188 |
| Net cash provided by financing activities | 19,277,144 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 7,186 |
| Net change in cash, cash equivalents and restricted cash | 9,013,182 |
| Cash, cash equivalents and restricted cash, beginning of year | 15,998,174 |
| Cash, cash equivalents and restricted cash, end of year | 25,011,356 |
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)